CDH2 and acute lymphoblastic leukemia: Indeed, Zang et al. reported that N-cadherin expression contributes to increased resistance to farnesyltransferase inhibitor SCH66336 in BCR-ABL1p190-positive acute lymphoblastic leukemia [27].